Stemline Therapeutics, Inc. (STML) PT Raised to $38.00 at HC Wainwright

Stemline Therapeutics, Inc. (NASDAQ:STML) had its price objective increased by HC Wainwright from $34.00 to $38.00 in a research note published on Wednesday, November 1st, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

STML has been the topic of several other reports. Zacks Investment Research cut Stemline Therapeutics from a hold rating to a sell rating in a research note on Tuesday, July 18th. ValuEngine cut Stemline Therapeutics from a hold rating to a sell rating in a research note on Thursday, August 10th. Cowen and Company restated a buy rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. Finally, BidaskClub upgraded Stemline Therapeutics from a hold rating to a buy rating in a research note on Wednesday, July 19th. Two investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. Stemline Therapeutics has a consensus rating of Buy and a consensus price target of $33.40.

Shares of Stemline Therapeutics (STML) traded up $0.10 during trading hours on Wednesday, reaching $14.10. The company’s stock had a trading volume of 250,800 shares, compared to its average volume of 280,453. Stemline Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $14.60.

ILLEGAL ACTIVITY WARNING: “Stemline Therapeutics, Inc. (STML) PT Raised to $38.00 at HC Wainwright” was first posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/markets/stemline-therapeutics-inc-stml-pt-raised-to-38-00/1748828.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STML. FMR LLC raised its stake in shares of Stemline Therapeutics by 72.1% during the 1st quarter. FMR LLC now owns 2,538,892 shares of the biopharmaceutical company’s stock worth $21,708,000 after purchasing an additional 1,063,457 shares during the period. Lyon Street Capital LLC raised its stake in shares of Stemline Therapeutics by 331.1% during the 3rd quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after purchasing an additional 415,867 shares during the period. Vanguard Group Inc. raised its stake in shares of Stemline Therapeutics by 32.9% during the 1st quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock worth $7,055,000 after purchasing an additional 204,228 shares during the period. AXA raised its stake in shares of Stemline Therapeutics by 44.9% during the 2nd quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock worth $5,789,000 after purchasing an additional 195,022 shares during the period. Finally, C WorldWide Group Holding A S bought a new stake in Stemline Therapeutics in the 3rd quarter valued at about $1,776,000. Institutional investors own 49.01% of the company’s stock.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Brandon Morrow Becomes Hot Commodity
Brandon Morrow Becomes Hot Commodity
Red Sox Want Sluggers, Giancarlo Stanton May Become Available
Red Sox Want Sluggers, Giancarlo Stanton May Become Available


Leave a Reply

 
© 2006-2017 BBNS.